Skip to content
Peptigraph home
Shop Peptides50% off*

CagriSema for Metabolism: What the Evidence Shows

What human and animal studies show about CagriSema for metabolism, how strong that evidence is, and what is still unproven.

Medical review pendingAmylin + GLP-1 combinationUpdated
Strongest evidence
Human RCT
Human studies
5
with an outcome for metabolism, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for metabolism, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
5
with an outcome for metabolism

Evidence for metabolism

Each row is an outcome related to metabolism from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

CagriSema for metabolism: outcomes in published studies
OutcomeResultStudy typeSource
HbA1c at week 40 (primary)HbA1c changed by -1·8 percentage points (2·4 mg each) and -1·5 (1·0 mg each) versus -0·1 with placebo at 40 weeks.Human RCTn = 189The lancet. Diabetes & endocrinology 2026, PMID 42251860
HbA1c vs semaglutide (primary)HbA1c fell by -1·91 percentage points with CagriSema versus -1·75 with semaglutide 2·4 mg (difference -0·16).Human RCTn = 2713The lancet. Diabetes & endocrinology 2026, PMID 42251859
HbA1c at week 40 (primary)HbA1c fell by -2·33% (2·4 mg each) and -2·10% (1·0 mg each) versus -0·66% with placebo at week 40 as add-on to basal insulin.Human RCTn = 274Lancet 2026, PMID 42251856
HbA1c of 6.5% or less73.5% reached a glycated hemoglobin level of 6.5% or less with CagriSema versus 15.9% with placebo.Human RCTn = 1206The New England journal of medicine 2025, PMID 40544432
HbA1c at week 32 (primary)HbA1c changed by -2·2 percentage points with CagriSema, -1·8 with semaglutide and -0·9 with cagrilintide; the difference was significant versus cagrilintide but not versus semaglutide.Human RCTn = 92Lancet 2023, PMID 37364590

CagriSema and metabolism are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The lancet. Diabetes & endocrinology 2026, PMID 42251860

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

What metabolic syndrome is

MedlinePlus defines metabolic syndrome as a group of risk factors for heart disease, diabetes and other health problems.[6]

Weight and glucose measures in the trials

In REIMAGINE 1 the combination cut body weight by 13.8% at 2.4 mg each over 40 weeks, a secondary measure.[1]

The 32-week phase 2 trial found fasting plasma glucose fell by 3.3 mmol/L with CagriSema, against 1.7 with cagrilintide alone.[5]

Continuous glucose monitoring in that trial showed time in range rising from 45.9% at baseline to 88.9% at week 32 with CagriSema.[5]

In REIMAGINE 3 the authors report that the HbA1c falls came with bodyweight reductions and no additional risk of hypoglycaemia.[3]

The REDEFINE 2 trial reported a body weight change of -13.7% on the combination against -3.4% on placebo at week 68.[4]

Other peptides people research for metabolism

RetatrutideTirzepatideMOTS-cHGHMazdutide
All peptides for metabolism, compared

Common questions

Does CagriSema help with metabolism?

The strongest study we summarise for metabolism is human rct evidence, across 5 studies with an outcome for metabolism. A trial result is not an approval; see the legal status.

Is CagriSema approved for metabolism?

No. CagriSema is not FDA approved for any use, including metabolism.

What is the best peptide for metabolism?

There is no single answer. Our metabolism overview compares each candidate by evidence grade and legal status rather than by popularity.

Is CagriSema a metabolism booster?

No study cited here measures metabolic rate; the trials report weight, HbA1c, glucose and blood pressure, such as weight reductions of 10-12% in the insulin add-on trial.[3]

More on CagriSema

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026PMID 42251860Accessed 2 Oct 2026
  2. 2Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026PMID 42251859Accessed 2 Oct 2026
  3. 3Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet (London, England) · 2026PMID 42251856Accessed 2 Oct 2026
  4. 4Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
  5. 5Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 2 Oct 2026
  6. 6Official web pageOfficial web page · web page

Found an error? Report a correction.